Inventory management for platelet components and of fibrinogen sources (cryoprecipitated antihemophilic factor) can be challenging given their short shelf-life.
An upcoming Science and Innovation Forum presented by Cerus Corporation will describe how pathogen-reduced platelets (Intercept Platelets) and pathogen-reduced cryoprecipitated fibrinogen complex (Intercept Fibrinogen Complex) may improve blood availability for patients in need.
This program will take place at 2 p.m. ET on Wednesday, Nov. 30. Registration is complimentary but required to attend.
